Antagonism of the effects of clonidine by the alpha 2-adrenoceptor antagonist, fluparoxan.
1. The effects of fluparoxan, an alpha 2-adrenoceptor antagonist, on the pharmacodynamic changes induced by clonidine were investigated in this placebo-controlled, double-blind, two-period, cross-over study in 16 healthy male volunteers (aged 19 to 44 years). 2. Subjects received either fluparoxan or placebo, twice-daily for 5 1/2 days (11 doses). One hour after the first and last dose of each treatment period, clonidine (200 micrograms) was infused intravenously over 5 min. 3. Indices of clonidine-mediated pharmacodynamic responses (growth hormone secretion, bradycardia, hypotension, xerostomia and sedation) were taken before and after clonidine infusion. Growth hormone secretion was assessed by quantifying serum growth hormone concentrations; sedation was assessed by both visual analogue scales (VAS) and by a visual psychomotor response meter, measuring critical flicker fusion (CFF). 4. The majority of subjects reported minor adverse events such as lethargy, headache and dry mouth following clonidine infusion. All adverse events were likely to be related to clonidine, as they occurred consistently between treatment groups. Fluparoxan has, however, in previous studies been reported to cause headache and light-headedness. 5. Prior to the clonidine infusion, fluparoxan caused small but statistically significant increases in systolic blood pressure (4 mm Hg) and salivary flow (approximately 30%) after both single and repeated doses. A small increase in heart rate (2 beats min-1) was seen after a single dose which was also statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)
Johnson
M A
MA
Clinical Pharmacology Division, Glaxo Research and Development Limited, Greenford, Middlesex, UK.
Blackwell
C P
CP
Smith
J
J
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D001919:Bradycardia / Q000139:chemically induced; D003000:Clonidine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D013006:Growth Hormone / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007262:Infusions, Intravenous; D008297:Male; D010883:Piperoxan / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D011597:Psychomotor Performance / Q000187:drug effects; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology*; D014987:Xerostomia / Q000139:chemically induced
D000317:Adrenergic alpha-Antagonists; D000928:Antidepressive Agents; D011758:Pyrroles; D013006:Growth Hormone; D010883:Piperoxan; D003000:Clonidine; C065161:fluparoxan